Illumina, Inc. (NASDAQ:ILMN – Get Rating) shares traded up 5.7% during mid-day trading on Wednesday . The company traded as high as $207.01 and last traded at $205.80. 36,952 shares were traded during mid-day trading, a decline of 97% from the average session volume of 1,461,272 shares. The stock had previously closed at $194.70.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the stock. Robert W. Baird reduced their price objective on shares of Illumina from $306.00 to $215.00 in a research report on Friday, August 12th. Canaccord Genuity Group reduced their price target on shares of Illumina from $450.00 to $380.00 and set a “buy” rating for the company in a research report on Friday, August 12th. Credit Suisse Group initiated coverage on shares of Illumina in a research report on Wednesday, August 24th. They issued a “neutral” rating and a $230.00 price target for the company. Cowen reduced their price target on shares of Illumina to $327.00 in a research report on Monday, August 15th. Finally, Barclays reduced their price target on shares of Illumina to $130.00 in a research report on Monday, August 15th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Illumina has an average rating of “Hold” and a consensus price target of $257.27.
Illumina Stock Performance
The company has a current ratio of 1.00, a quick ratio of 0.82 and a debt-to-equity ratio of 0.05. The firm has a fifty day simple moving average of $206.99 and a 200 day simple moving average of $247.75.
Insider Transactions at Illumina
In other news, SVP Alexander Aravanis sold 539 shares of the firm’s stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $200.00, for a total value of $107,800.00. Following the sale, the senior vice president now owns 3,346 shares in the company, valued at $669,200. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Illumina
A number of institutional investors have recently bought and sold shares of ILMN. Private Trust Co. NA acquired a new stake in Illumina during the second quarter worth $25,000. Glassman Wealth Services boosted its stake in Illumina by 72.9% during the second quarter. Glassman Wealth Services now owns 147 shares of the life sciences company’s stock worth $27,000 after buying an additional 62 shares in the last quarter. Asset Dedication LLC lifted its holdings in shares of Illumina by 75.0% during the first quarter. Asset Dedication LLC now owns 77 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 33 shares during the period. Farmers & Merchants Investments Inc. bought a new position in shares of Illumina during the first quarter valued at $30,000. Finally, Tcwp LLC bought a new position in shares of Illumina during the first quarter valued at $31,000. Institutional investors and hedge funds own 86.12% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
- Get a free copy of the StockNews.com research report on Illumina (ILMN)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.